Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment Effectiveness of Avelumab First-Line Maintenance Among Canadian Patients With Advanced Urothelial Carcinoma (TRAVELER)

NCT05699135 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05699135
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05699135 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment Effectiveness of Avelumab First-Line Maintenance Among Canadian Patients With Advanced Urothelial Carcinoma (TRAVELER)
Lead sponsor
Pfizer
Phase
Observational
Overall status
Terminated
Start date
March 9, 2023
Completion date
June 30, 2023
Enrollment
150 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, bladder tumors, urinary bladder neoplasms, urothelial carcinoma